Hybridoma Sequencing
Hybridoma sequencing involves the genomic sequencing of cells generated through hybridoma technology, which is crucial for exploring the genomic composition of hybridoma cells. These cells are produced in laboratories by fusing antibody-producing B lymphocytes with immortalized myeloma cells, resulting in cell lines capable of both indefinite proliferation and antibody secretion. This technique underpins the production of monoclonal antibodies, essential for creating cells that retain the specificity of B lymphocytes and the proliferative features of myeloma cells. The goal of hybridoma sequencing is to deliver comprehensive genetic insights into these cells, an indispensable step in monoclonal antibody drug development. The sequencing results can refine antibody properties such as affinity, stability, and efficacy, advancing drug efficacy. In cancer treatment, monoclonal antibody drugs are continuously refined through this process to enhance targeting and therapeutic outcomes. The importance of hybridoma sequencing is significant; it allows researchers to decode hybridoma genomic structures, unveil regulatory mechanisms of antibody production, and identify genetic factors potentially causing hybridoma instability. Moreover, it aids in discovering unique antibody gene sequences, informing antibody production optimization.
Sequencing Process
1.DNA Extraction
Genomic DNA or mRNA is extracted from hybridoma cells. When mRNA is extracted, it is reverse-transcribed into cDNA, which conveniently retains only coding sequences, facilitating subsequent sequencing.
2. Primer Design
Primers are developed based on known antibody gene sequences. Conserved sequences within the variable regions of antibody chains serve as targets, and the primer quality is critical for sequencing precision and completeness.
3. PCR Amplification
Designed primers amplify target antibody gene fragments via polymerase chain reaction (PCR), increasing fragment quantities for sequencing. PCR conditions are meticulously controlled to ensure specific and efficient amplification.
4. Choice of Sequencing Technology
(1) Sanger Sequencing: Preferred for its long read lengths and high accuracy, suitable for sequencing few hybridoma-derived antibodies, despite its low throughput.
(2) Next-Generation Sequencing (NGS): Technologies like Illumina allow high-throughput sequencing of multiple samples, though they often require more complex data processing due to shorter read lengths.
5. Data Analysis
Sequenced data is analyzed through assembly, alignment, and annotation. Comparison with antibody gene databases helps determine gene types, families, and unique sequences, also analyzing mutations and glycosylation sites affecting function.
Purpose of Hybridoma Sequencing
1. Antibody Gene Identification
Sequencing pinpoints the gene sequences of antibodies, clarifying variable regions that dictate antigen specificity.
2. Quality Control
Ensures monoclonal antibody research and production consistency, verifying genetic stability across production batches.
3. New Antibody Discovery
Potential to discover antibodies with novel antigen-binding properties, aiding drug development and diagnostics.
Hybridoma sequencing offers high sensitivity and resolution, surpassing traditional methods by accurately identifying genomic mutations and variations. MtoZ Biolabs specializes in comprehensive hybridoma sequencing services, leveraging advanced platforms and bioinformatics expertise for detailed genomic analysis. For inquiries or assistance with hybridoma sequencing, please contact our expert team.
MtoZ Biolabs, an integrated chromatography and mass spectrometry (MS) services provider.
Related Services
How to order?
